Over the years, Pharco has grown into a global pharmaceutical company with a presence across multiple regions. We continue to expand access to essential medicines while supporting healthcare systems and improving patient outcomes worldwide.
Pharco delivers medicines across global pharmaceutical markets through strong partnerships with healthcare providers and distribution networks. With a focus on access to essential medicines, we support patient care and ensure consistent supply across regions through our international pharmaceutical distribution and export operations
Pharco contributed to hepatitis C elimination efforts by expanding treatment access through national programs, working closely with healthcare authorities to reach millions of patients and supporting global health initiatives.
Through collaboration with public health partners, Pharco improved access to bilharzia treatment and supported national control programs addressing neglected tropical diseases.
Egypt's medical tourism initiative offers international Hepatitis C patients fast, affordable treatment with no waiting time, alongside a five-star stay and the chance to experience Egypt's historic landmarks during recovery. Program ambassadors include Lionel Messi, Dani Alves, Ahmed Hossam (Mido) and Mohamed Hamaki.
Pharco in the Media
Speaking to CNN's Marketplace Africa, Pharco Corporation's Chairman sets out how Egypt turned an affordable Hepatitis C cure into a national elimination programme, and what that model means for access to medicine across Africa and the Middle East.
Watch the InterviewPharco's commitment to quality and compliance has earned recognition from the world's most respected regulatory and health authorities.
Stay updated with Pharco's latest developments, research progress, and partnerships shaping the future of healthcare.
Pharco has switched on a new eye drops production line at its Amreya City site in Alexandria. Alongside it, the company is launching a broader push to get more people across Egypt and the region screened for eye disease before it does lasting damage.
Pharco and Saudi German Health Egypt & North Africa signed a strategic memorandum of understanding on June 15, 2026, on the sidelines of Africa Health ExCon 2026 in Cairo. The agreement goes beyond a standard supply arrangement: it covers pharmaceutical supply chain logistics, ongoing training for medical professionals, scientific exchange, and joint sponsorship of healthcare initiatives and medical congresses.
Pharco is building a pharmaceutical plant in Saudi Arabia, and Ashmore Investment Saudi Arabia is putting capital behind it. The deal, signed at the PIF Private Sector Forum, is the first investment under Ashmore's Industrial Initiative, and it hands Pharco's Saudi arm, Pharco KSA, fresh money to get the plant built.
